Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.
Stocks · News reference
Wedbush has downgraded Aclaris Therapeutics from Outperform to Neutral and reduced its price target for the company's stock.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aclaris Therapeutics misses Phase 2 bosakitug endpoints but launches its Phase 2b modzatinib trial for moderate-to-severe lichen planus.
Aclaris Therapeutics reported that its Phase 2 ADMIRATION trial evaluating bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis did not meet its primary endpoint.
Aclaris Therapeutics has commenced a Phase 2b clinical trial for its treatment candidate, modzatinib, targeting lichen planus.
Filed: 2026-11-16 AccNo: 0001104659-26-127478 Size: 432 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Aclaris Therapeutics announced that its CEO and senior leadership team will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference.
Aclaris Therapeutics announced its Q3 2026 financial results and provided updates on its clinical pipeline, including progress on Modzatinib, Bosakitug, and ATI-052.